IMNM

Rating neutralAI MemoPost-earnings T+1

Immunome

As of 2026-05-08/Post-earnings T+1/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-08 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Varegacestat NDA submission shifts focus to FDA review clarity • 2026-07-31

Expected move: -9%

Biggest risk

This remains a cautious monitoring setup because Immunome still has no approved products, pipeline value is heavily concentrated in varegacestat, and as of May 8, 2026 I did not find a company Q1 2026 earnings release or 8-K to refresh near-term cash-burn and operating visibility. T+1 analyst revision and surprise framing therefore remain unavailable rather than supportive.

Invalidation

Break below $14 or thesis failure.

What would change my mind?

The strongest update since the prior baseline is real primary-source confirmation that varegacestat has moved from planned filing to submitted NDA status on April 29, 2026, with ASCO oral data close behind. If investors gain confidence that the FDA review proceeds normally and the detailed RINGSIDE presentation supports the topline profile, IMNM can still rerate despite the negative deterministic prior.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-05-08

Base target

$21

p=45%

Bull target

$30

p=25%

Bear target

$14

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Detailed RINGSIDE data set for ASCO oral presentation on May 30, 2026
IM-1021 initial Phase 1 data remain the key second-asset validation point in 2026
The strongest update since the prior baseline is real primary-source confirmation that varegacestat has moved from planned filing to submitted NDA status on April 29, 2026, with ASCO oral data close behind.

BearKey bullets

As of May 8, 2026, Immunome's investor-relations news page showed releases through May 5, 2026 but no Q1 2026 financial-results release, leaving the scheduled post-earnings follow-up with limited fresh operating disclosure.
[#IR-NEWS-2026-05-08]
Even with runway projected into 2028 from the March 3, 2026 update, Immunome is still a cash-burning biotech and future dilution risk is reduced rather than eliminated.

WatchKey bullets

Varegacestat NDA submission shifts focus to FDA review clarity

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+1

Base case: $21 (p=45%)

Bull/Bear spread: +30% / -39%

Vs latest close: Bull +30% · Base -9% · Bear -39%

Scenario probabilities

Bull Target: $30 (p=25%)Base Target: $21 (p=45%)Bear Target: $14 (p=30%)

Commentary

Primary-source news flow in the last month has been constructive because it moved from planned NDA language to a confirmed April 29, 2026 submission and a dated May 30 ASCO oral presentation. But this was supposed to be a T+1 post-earnings follow-up for May 7, 2026, and I did not find a matching company earnings release or 8-K by May 8, 2026, so earnings surprise, guidance revision and analyst post-print reaction are unavailable rather than positive evidence. Market reaction also looks muted so far: IMNM was about $22.24 on May 8, 2026 versus the prior $22.19 close.

As of 2026-05-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Detailed RINGSIDE data set for ASCO oral presentation on May 30, 2026
IM-1021 initial Phase 1 data remain the key second-asset validation point in 2026

Scenarios

Bull Target (Scenario probability)

$30 / p=25% prob

Base Target (Scenario probability)

$21 / p=45% prob

Bear Target (Scenario probability)

$14 / p=30% prob

Price $23 as of 2026-08-03

Nearest Scenario: Base (∆ 9%)

Targets vs latest close: Bull +30% · Base -9% · Bear -39%

Sentiment & Exposure

News Sentiment (30d)

0.25

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-07-31
Varegacestat NDA submission shifts focus to FDA review clarity
Immunome announced on April 29, 2026 that it submitted the NDA for varegacestat in adults with desmoid tumors, supported by Phase 3 RINGSIDE results showing a hazard ratio of 0.16 for progression-free survival and a 56% objective response rate. The filing is a real de-risking step, but the stock likely still needs clearer FDA review visibility and eventual regulatory acceptance to sustain a rerating. [#PR-2026-04-29] [#10-K-2026-03-03]
Prob 75.00% • Move 16.00% • Priced-in 60.00%

Short-term Catalysts

Next few weeks

Detailed RINGSIDE data set for ASCO oral presentation on May 30, 2026
2026-05-30
Immunome said detailed Phase 3 RINGSIDE data were selected for an oral abstract session at the 2026 ASCO Annual Meeting on May 30, 2026. After the April 29 NDA submission, fuller efficacy and tolerability detail could help investors judge durability, clinical differentiation and eventual launch potential beyond the topline data already disclosed. [#PR-2026-04-21] [#PR-2026-04-29]
Prob 90% • Move 10% • Priced-in 65%

Long-term Catalysts

Months to a year

IM-1021 initial Phase 1 data remain the key second-asset validation point in 2026
2026-12-31
Management said IM-1021 Phase 1 is ongoing and initial data are expected in 2026. With varegacestat now in regulatory review, meaningful read-through from IM-1021 would matter disproportionately for showing that Immunome is more than a single-asset desmoid story, but early oncology data remain volatile. [#10-K-2026-03-03] [#8-K-2026-03-03]
Prob 60% • Move 22% • Priced-in 35%

Risks

As of May 8, 2026, Immunome's investor-relations news page showed releases through May 5, 2026 but no Q1 2026 financial-results release, leaving the scheduled post-earnings follow-up with limited fresh operating disclosure. [#IR-NEWS-2026-05-08]
Even with runway projected into 2028 from the March 3, 2026 update, Immunome is still a cash-burning biotech and future dilution risk is reduced rather than eliminated. [#8-K-2026-03-03] [#10-K-2026-03-03]
The April 29, 2026 NDA submission does not remove approval risk; Immunome explicitly flagged possible delay, non-approval, labeling and commercialization risks for varegacestat. [#PR-2026-04-29]
The company remains pre-commercial and highly dependent on a small number of pipeline programs, so any regulatory setback for varegacestat or weak IM-1021 data would likely have an outsized impact.

Peers

Symbol	Summary
CLDX	Celldex is the closest candidate in the provided set for a development-stage biotech valuation comparison: event-driven, cash-burn funded and reliant on clinical execution, though it is not a direct desmoid or ADC peer.
IRON	Disc Medicine is mainly a size-matched development-stage biotech benchmark rather than a direct oncology comparator; it is useful for framing how mid-cap biotech valuations still depend on milestone delivery and financing overhang compression.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Human targets: serper
Analysis date: 2026-05-08

AI Stock Memo: IMNM - Immunome - RankAlpha